Perhaps a more cost-effective option lies in developing vaccines using common cancer-associated antigens (CAAs), which in theory could treat a large number of tumours.
This report aims to provide a comprehensive presentation of the global market for Common Cancer-associated Antigens (CAAs) Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Common Cancer-associated Antigens (CAAs) Vaccine. This report contains market size and forecasts of Common Cancer-associated Antigens (CAAs) Vaccine in global, including the following market information:
Global Common Cancer-associated Antigens (CAAs) Vaccine Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Common Cancer-associated Antigens (CAAs) Vaccine market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Tecemotide Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Common Cancer-associated Antigens (CAAs) Vaccine include Seattle Genetics, Merck Serono, Merck KGaA, GlaxoSmithKline, KAEL-GemVax, SELLAS Life Sciences, Celldex and Immatics Biotechnologies, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Common Cancer-associated Antigens (CAAs) Vaccine companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Common Cancer-associated Antigens (CAAs) Vaccine Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Common Cancer-associated Antigens (CAAs) Vaccine Market Segment Percentages, by Type, 2022 (%)
Tecemotide
Astuprotimut-R
Tertomotide
Nelipepimut-S
Others
Global Common Cancer-associated Antigens (CAAs) Vaccine Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Common Cancer-associated Antigens (CAAs) Vaccine Market Segment Percentages, by Application, 2022 (%)
Pediatrics
Adults
Global Common Cancer-associated Antigens (CAAs) Vaccine Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Common Cancer-associated Antigens (CAAs) Vaccine Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Common Cancer-associated Antigens (CAAs) Vaccine revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Common Cancer-associated Antigens (CAAs) Vaccine revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Seattle Genetics
Merck Serono
Merck KGaA
GlaxoSmithKline
KAEL-GemVax
SELLAS Life Sciences
Celldex
Immatics Biotechnologies
Outline of Major Chapters:
Chapter 1: Introduces the definition of Common Cancer-associated Antigens (CAAs) Vaccine, market overview.
Chapter 2: Global Common Cancer-associated Antigens (CAAs) Vaccine market size in revenue.
Chapter 3: Detailed analysis of Common Cancer-associated Antigens (CAAs) Vaccine company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Common Cancer-associated Antigens (CAAs) Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Common Cancer-associated Antigens (CAAs) Vaccine Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Common Cancer-associated Antigens (CAAs) Vaccine Overall Market Size
2.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size: 2022 VS 2030
2.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Common Cancer-associated Antigens (CAAs) Vaccine Players in Global Market
3.2 Top Global Common Cancer-associated Antigens (CAAs) Vaccine Companies Ranked by Revenue
3.3 Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue by Companies
3.4 Top 3 and Top 5 Common Cancer-associated Antigens (CAAs) Vaccine Companies in Global Market, by Revenue in 2022
3.5 Global Companies Common Cancer-associated Antigens (CAAs) Vaccine Product Type
3.6 Tier 1, Tier 2 and Tier 3 Common Cancer-associated Antigens (CAAs) Vaccine Players in Global Market
3.6.1 List of Global Tier 1 Common Cancer-associated Antigens (CAAs) Vaccine Companies
3.6.2 List of Global Tier 2 and Tier 3 Common Cancer-associated Antigens (CAAs) Vaccine Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Markets, 2022 & 2030
4.1.2 Tecemotide
4.1.3 Astuprotimut-R
4.1.4 Tertomotide
4.1.5 Nelipepimut-S
4.1.6 Others
4.2 By Type - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue & Forecasts
4.2.1 By Type - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2018-2023
4.2.2 By Type - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2024-2030
4.2.3 By Type - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2022 & 2030
5.1.2 Pediatrics
5.1.3 Adults
5.2 By Application - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue & Forecasts
5.2.1 By Application - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2018-2023
5.2.2 By Application - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2024-2030
5.2.3 By Application - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2022 & 2030
6.2 By Region - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue & Forecasts
6.2.1 By Region - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2018-2023
6.2.2 By Region - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2024-2030
6.2.3 By Region - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2018-2030
6.3.2 US Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2018-2030
6.3.3 Canada Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2018-2030
6.3.4 Mexico Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2018-2030
6.4.2 Germany Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2018-2030
6.4.3 France Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2018-2030
6.4.4 U.K. Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2018-2030
6.4.5 Italy Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2018-2030
6.4.6 Russia Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2018-2030
6.4.7 Nordic Countries Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2018-2030
6.4.8 Benelux Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2018-2030
6.5.2 China Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2018-2030
6.5.3 Japan Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2018-2030
6.5.4 South Korea Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2018-2030
6.5.5 Southeast Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2018-2030
6.5.6 India Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2018-2030
6.6.2 Brazil Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2018-2030
6.6.3 Argentina Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2018-2030
6.7.2 Turkey Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2018-2030
6.7.3 Israel Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2018-2030
6.7.4 Saudi Arabia Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2018-2030
6.7.5 UAE Common Cancer-associated Antigens (CAAs) Vaccine Market Size, 2018-2030
7 Common Cancer-associated Antigens (CAAs) Vaccine Companies Profiles
7.1 Seattle Genetics
7.1.1 Seattle Genetics Company Summary
7.1.2 Seattle Genetics Business Overview
7.1.3 Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine Major Product Offerings
7.1.4 Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global Market (2018-2023)
7.1.5 Seattle Genetics Key News & Latest Developments
7.2 Merck Serono
7.2.1 Merck Serono Company Summary
7.2.2 Merck Serono Business Overview
7.2.3 Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine Major Product Offerings
7.2.4 Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global Market (2018-2023)
7.2.5 Merck Serono Key News & Latest Developments
7.3 Merck KGaA
7.3.1 Merck KGaA Company Summary
7.3.2 Merck KGaA Business Overview
7.3.3 Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine Major Product Offerings
7.3.4 Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global Market (2018-2023)
7.3.5 Merck KGaA Key News & Latest Developments
7.4 GlaxoSmithKline
7.4.1 GlaxoSmithKline Company Summary
7.4.2 GlaxoSmithKline Business Overview
7.4.3 GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine Major Product Offerings
7.4.4 GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global Market (2018-2023)
7.4.5 GlaxoSmithKline Key News & Latest Developments
7.5 KAEL-GemVax
7.5.1 KAEL-GemVax Company Summary
7.5.2 KAEL-GemVax Business Overview
7.5.3 KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine Major Product Offerings
7.5.4 KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global Market (2018-2023)
7.5.5 KAEL-GemVax Key News & Latest Developments
7.6 SELLAS Life Sciences
7.6.1 SELLAS Life Sciences Company Summary
7.6.2 SELLAS Life Sciences Business Overview
7.6.3 SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Major Product Offerings
7.6.4 SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global Market (2018-2023)
7.6.5 SELLAS Life Sciences Key News & Latest Developments
7.7 Celldex
7.7.1 Celldex Company Summary
7.7.2 Celldex Business Overview
7.7.3 Celldex Common Cancer-associated Antigens (CAAs) Vaccine Major Product Offerings
7.7.4 Celldex Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global Market (2018-2023)
7.7.5 Celldex Key News & Latest Developments
7.8 Immatics Biotechnologies
7.8.1 Immatics Biotechnologies Company Summary
7.8.2 Immatics Biotechnologies Business Overview
7.8.3 Immatics Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Major Product Offerings
7.8.4 Immatics Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global Market (2018-2023)
7.8.5 Immatics Biotechnologies Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Common Cancer-associated Antigens (CAAs) Vaccine Market Opportunities & Trends in Global Market
Table 2. Common Cancer-associated Antigens (CAAs) Vaccine Market Drivers in Global Market
Table 3. Common Cancer-associated Antigens (CAAs) Vaccine Market Restraints in Global Market
Table 4. Key Players of Common Cancer-associated Antigens (CAAs) Vaccine in Global Market
Table 5. Top Common Cancer-associated Antigens (CAAs) Vaccine Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Share by Companies, 2018-2023
Table 8. Global Companies Common Cancer-associated Antigens (CAAs) Vaccine Product Type
Table 9. List of Global Tier 1 Common Cancer-associated Antigens (CAAs) Vaccine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Common Cancer-associated Antigens (CAAs) Vaccine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Common Cancer-associated Antigens (CAAs) Vaccine Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2024-2030
Table 30. Seattle Genetics Company Summary
Table 31. Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine Product Offerings
Table 32. Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$, Mn) & (2018-2023)
Table 33. Seattle Genetics Key News & Latest Developments
Table 34. Merck Serono Company Summary
Table 35. Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine Product Offerings
Table 36. Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$, Mn) & (2018-2023)
Table 37. Merck Serono Key News & Latest Developments
Table 38. Merck KGaA Company Summary
Table 39. Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine Product Offerings
Table 40. Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$, Mn) & (2018-2023)
Table 41. Merck KGaA Key News & Latest Developments
Table 42. GlaxoSmithKline Company Summary
Table 43. GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine Product Offerings
Table 44. GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$, Mn) & (2018-2023)
Table 45. GlaxoSmithKline Key News & Latest Developments
Table 46. KAEL-GemVax Company Summary
Table 47. KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine Product Offerings
Table 48. KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$, Mn) & (2018-2023)
Table 49. KAEL-GemVax Key News & Latest Developments
Table 50. SELLAS Life Sciences Company Summary
Table 51. SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Product Offerings
Table 52. SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$, Mn) & (2018-2023)
Table 53. SELLAS Life Sciences Key News & Latest Developments
Table 54. Celldex Company Summary
Table 55. Celldex Common Cancer-associated Antigens (CAAs) Vaccine Product Offerings
Table 56. Celldex Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$, Mn) & (2018-2023)
Table 57. Celldex Key News & Latest Developments
Table 58. Immatics Biotechnologies Company Summary
Table 59. Immatics Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Product Offerings
Table 60. Immatics Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Revenue (US$, Mn) & (2018-2023)
Table 61. Immatics Biotechnologies Key News & Latest Developments
List of Figures
Figure 1. Common Cancer-associated Antigens (CAAs) Vaccine Segment by Type in 2022
Figure 2. Common Cancer-associated Antigens (CAAs) Vaccine Segment by Application in 2022
Figure 3. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Common Cancer-associated Antigens (CAAs) Vaccine Revenue in 2022
Figure 8. By Type - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2018-2030
Figure 9. By Application - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2018-2030
Figure 10. By Type - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2018-2030
Figure 12. By Application - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2018-2030
Figure 14. By Region - Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2018-2030
Figure 15. By Country - North America Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2018-2030
Figure 16. US Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2018-2030
Figure 20. Germany Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2030
Figure 21. France Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2018-2030
Figure 28. China Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2030
Figure 32. India Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2018-2030
Figure 34. Brazil Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share, 2018-2030
Figure 37. Turkey Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Common Cancer-associated Antigens (CAAs) Vaccine Revenue, (US$, Mn), 2018-2030
Figure 41. Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Celldex Common Cancer-associated Antigens (CAAs) Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Immatics Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
